Trilaciclib is a CDK4/6 Inhibitor for Kinds of Cancer Research
CDK4/6 is a Ser/Thr protein kinase that is active only in the G1-S phase. It is controlled by the regulatory subunit D-type cyclin and the CDK inhibitor p16INK4a; involved in the…
CDK4/6 is a Ser/Thr protein kinase that is active only in the G1-S phase. It is controlled by the regulatory subunit D-type cyclin and the CDK inhibitor p16INK4a; involved in the…
Acute myeloid leukemia (AML) is a group of malignant diseases of the hematopoietic system. And, AML occurs as the result of mutations in hematopoietic stem/progenitor cells. Despite advances in treatment,…
PD-1 (Programmed cell death protein 1; CD279) is an immune checkpoint. PD-1 is a cell surface receptor that belongs to the immunoglobulin superfamily. Besides, It shows a role in regulating…
ADAM metallopeptidase domain 17 (ADAM17) is an enzyme that belongs to the ADAM protein family of metalloproteases. ADAM17 plays a prominent role in the Notch signaling pathway. In this study,…
DNA-damaging chemotherapeutics, such as Cisplatin, have been the mainstay of cancer treatment for decades. These therapies generate DNA lesions, and high-fidelity replicative DNA polymerases as the template cannot utilization. Thus,…
Genetic alterations that disable G1/S checkpoint control and loss of this checkpoint often happen in human cancer. The mechanisms contribute to cancer generation by permitting inappropriate proliferation and distorting fate-driven…
In previous blog, we described NG25 as a potent dual TAK1 and MAP4K2 inhibitor. The compound shows excellent inhibition for inhibiting IKKβ activation by TLR7 and TLR9 agonists. Today, I’d…
Nerves carry messages from the brain to the rest of the body. Peripheral neuropathy occurs when the peripheral nervous system is damaged. Chemotherapy-induced peripheral neuropathy is one of the most commonly…